Australia is closely awaiting the arrival of retatrutide, a groundbreaking dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, https://aishawiqo160943.diowebhost.com/98060003/novo-nordisk-s-retatrutide-australia-a-promising-breakthrough-for-weight-management